Spark Therapeutics (ONCE) Stock Rating Lowered by UBS
Spark Therapeutics (NASDAQ:ONCE) was downgraded by stock analysts at UBS from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday. They presently have a $51.00 price objective on the biotechnology company’s stock, down from their prior price objective of $92.00. UBS’s target price suggests a potential upside of 11.09% from the stock’s previous close.
A number of other equities analysts also recently issued reports on the company. ValuEngine downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. BMO Capital Markets reiterated a “buy” rating and set a $101.00 price target on shares of Spark Therapeutics in a research note on Wednesday, November 15th. Cantor Fitzgerald reiterated a “buy” rating and set a $105.00 price target (up previously from $94.00) on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Goldman Sachs Group reiterated a “buy” rating and set a $111.00 price target on shares of Spark Therapeutics in a research note on Friday, October 6th. Finally, Barclays lifted their price target on Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $76.19.
Spark Therapeutics (NASDAQ ONCE) opened at $45.91 on Tuesday. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. Spark Therapeutics’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.07) EPS. equities analysts expect that Spark Therapeutics will post -7.6 EPS for the current year.
In related news, insider Daniel Faga sold 1,500 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the sale, the insider now owns 1,500 shares of the company’s stock, valued at approximately $127,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $86.16, for a total transaction of $430,800.00. Following the completion of the sale, the insider now directly owns 215,000 shares in the company, valued at approximately $18,524,400. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,068,809 shares of company stock worth $89,809,385. Insiders own 7.30% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its holdings in shares of Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Spark Therapeutics in the 2nd quarter worth approximately $143,000. BNP Paribas Arbitrage SA raised its holdings in shares of Spark Therapeutics by 530.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 2,449 shares during the period. Pacad Investment Ltd. raised its holdings in shares of Spark Therapeutics by 75.0% in the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 1,500 shares during the period. Finally, Teacher Retirement System of Texas bought a new stake in shares of Spark Therapeutics in the 3rd quarter worth approximately $225,000. 94.94% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/14/spark-therapeutics-once-stock-rating-lowered-by-ubs.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.